Results 101 to 110 of about 32,416 (217)

Development of Streptococcus pneumoniae Vaccines Using Live Vectors [PDF]

open access: yes, 2015
: Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular ...

core   +1 more source

Factors associated with potentially inappropriate medication use, medication underuse and overuse in older adults in the German National Cohort

open access: yesJournal of Internal Medicine, Volume 299, Issue 6, Page 754-775, June 2026.
Abstract Background Effectively identifying individuals exposed to drug underuse, overuse and potentially inappropriate medication (PIM) in older adults is essential for minimizing preventable drug‐related harms. Methods We analysed data from 54,296 individuals aged 60–74 years from the German National Cohort (NAKO).
Miriam Degen   +18 more
wiley   +1 more source

Recombinant plants provide a new approach to the production of bacterial polysaccharide for vaccines. [PDF]

open access: yes, 2014
Bacterial polysaccharides have numerous clinical or industrial uses. Recombinant plants could offer the possibility of producing bacterial polysaccharides on a large scale and free of contaminating bacterial toxins and antigens.
G. C. Whitelam (7665758)   +58 more
core   +1 more source

Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.

open access: yes, 2014
BACKGROUND: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type
Lowe-Jallow, Y   +6 more
core   +1 more source

State of pneumococcal vaccine immunity

open access: yesHuman Vaccines & Immunotherapeutics
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae. Although antibodies against
Mustafa Akkoyunlu
doaj   +1 more source

Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review

open access: yesHuman Vaccines & Immunotherapeutics
Immunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease.
Vijay Yewale   +4 more
doaj   +1 more source

Identification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay

open access: yesVaccines
Multivalent pneumococcal vaccines have been developed successfully to combat invasive pneumococcal diseases (IPD) and reduce the associated healthcare burden.
James Z. Deng   +10 more
doaj   +1 more source

Age at First RSV Hospitalisation and the Risk of Subsequent Bacterial Pneumonia

open access: yes
Acta Paediatrica, Volume 115, Issue 6, Page 1298-1300, June 2026.
Samuel Videholm   +4 more
wiley   +1 more source

Potential serotype coverage of three pneumococcal conjugate vaccines against invasive pneumococcal infection in Italian children

open access: yes, 2012
Since the introduction of the 7-valent vaccine, invasive pneumococcal disease have greatly decreased; however, changes in the distribution of pneumococcal serotypes have recently highlighted the need for vaccines with wider coverage.
Valleriani, Claudia   +22 more
core   +1 more source

Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial

open access: yes, 2014
BACKGROUND: In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7) or 13-valent (PCV-13) pneumococcal conjugate vaccine at 2, 4 and 12 months of age.
Trück, J   +50 more
core   +1 more source

Home - About - Disclaimer - Privacy